JOURNAL LINFORMATIONBusiness Directories,Company Directories

Company Name: Corporate Name:	JOURNAL LINFORMATION
Company Title:
Company Description:
Keywords to Search:
Company Address:	135 Av Doucet,MONT-JOLI,QC,Canada
ZIP Code: Postal Code:	G5H1R6
Telephone Number:	4187754381
Fax Number:	4187757768
Website:
Email:
USA SIC Code(Standard Industrial Classification Code):	271101
USA SIC Description:	Newspapers (Publishers)
Number of Employees:	20 to 49
Sales Amount:	$5 to 10 million
Credit History: Credit Report:	Excellent
Contact Person:	Francis Dersrosier
Remove my name

Company Directories & Business Directories

copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)

Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Previous company profile:
LHIBOU-COUP INC
JULIEN THERIAULT CONSTRUCTION
JOURNAL LINFORMATION HEBDO REG

Next company profile:
JOLY, DIANE OD
JEAN-PIERRE ST-AMAND INC
J P REPARATION TRANS METAL

Company News:

The New England Journal of Medicine | Research Review Articles on . . .
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of
new england journal
5 cm; or T3, >5 cm) — that was treated with mastectomy, an axillary procedure, and systemic therapy Patients were assigned to undergo chest-wall irradiation (40 to 50 Gy; the irradiation group
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer
Current Issue | New England Journal of Medicine
Explore the current issue of The New England Journal of Medicine (Vol 393 No 21)
Medical Management and Revascularization for Asymptomatic Carotid . . .
Improvements in medical therapy, carotid-artery stenting, and carotid endarterectomy call into question the preferred management of asymptomatic carotid stenosis Whether adding revascularization t
Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream . . .
Bloodstream infections are associated with substantial morbidity and mortality Early, appropriate antibiotic therapy is important, but the duration of treatment is uncertain In a multicenter, non
Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer
Background First-line treatment with encorafenib plus cetuximab (EC) with or without chemotherapy (oxaliplatin, leucovorin, and fluorouracil [mFOLFOX6]) for BRAF V600E–mutated metastatic
Male-Partner Treatment to Prevent Recurrence of Bacterial Vaginosis
Bacterial vaginosis affects one third of reproductive-aged women, and recurrence is common Evidence of sexual exchange of bacterial vaginosis–associated organisms between partners suggests that
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
Imlunestrant is a next-generation, brain-penetrant, oral selective estrogen-receptor (ER) degrader that delivers continuous ER inhibition, even in cancers with mutations in the gene encoding ERα